 SAN DIEGO, June 3, 2021 PRNewswire -- Kintara Therapeutics, Inc. Nasdaq: KTRA Kintara or the Company, a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it has enrolled the final patient in the adjuvant arm of its ongoing Phase 2 clinical study of VAL-083 being conducted at the MD Anderson Cancer Center MD Anderson. The adjuvant arm of the study investigates newly-diagnosed patients suffering from glioblastoma multiforme GBM receiving VAL-083 in place of standard of care temozolomide TMZ as adjuvant therapy following surgery and chemoradiation TMZ. 